促红细胞生成素对慢性充血性心力衰竭患者血清脑钠肽、基质金属蛋白酶-9及左心室质量指数的影响  

Effect of erythropoietin on serum B-type natriuretic peptide,matrix metalloproteinase-9 and left ventricular mass index in patients with congestive heart failure

作　　者：李劲草 黄冰生 林桂雄 程颖 

机构地区：[1]广州市番禺区何贤纪念医院心内科,511400

出　　处：《新医学》2012年第7期450-453,共4页Journal of New Medicine

基　　金：广州市番禺区科技局基金项目(2011-Z-03-39)

摘　　要：目的:探讨促红细胞生成素(EPO)对慢性充血性心力衰竭(CHF)患者血清脑钠肽、基质金属蛋白酶-9(MMP-9)及左心室质量指数(LVMI)的影响。方法:79例CHF住院患者随机分为EPO治疗组及常规治疗组,同期门诊健康体检者79名为对照组。研究期为3个月,所有研究对象在研究初始及研究结束时均接受血红蛋白、血清脑钠肽、血清MMP-9及LVMI检测,记录两研究组患者心血管事件及不良反应的发生率,并进行比较。结果:研究结束时,EPO治疗组患者的脑钠肽、MMP-9水平比常规治疗组比较明显降低(P均<0.01),且血红蛋白水平比常规治疗组明显升高(P<0.05)。EPO治疗组患者LVMI及心血管事件发生率较常规治疗组有所降低,但比较差异无统计学意义(P>0.05)。EPO治疗组患者未发现明显不良反应。结论:予CHF患者加用小剂量EPO无明显不良反应,并可明显降低其贫血发生率、血清脑钠肽及MMP-9水平,且有降低其LVMI的趋势。Objectives： To investigate the effects of erythropoietin （EPO） on serum B-type natriuretic peptide （ BNP）, matrix metalloproteinase-9 （MMP-9） and left ventricular mass index （LVMI） in patients with congestive heart failure （CHF）. Methods： Each 79 patients with CHF and health people were recruited. Patients with CHF were randomly divided into two groups： general therapy group and EPO therapy group. All subjects were followed up for 3 months. The levels of Hb, serum BNP, MMP-9 and LVMI were examined. The incidences of cardiovascu- lar events and adverse reactions were assessed. Results： At the end of this study, the serum BNP and MMP-9 were significantly reduced in EPO therapy group, when comparing with those in general therapy group （ P 〈 0.05 ）. Al- though LVMI and cardiac events were reduced in EPO therapy group in contrast to general therapy group, there was no significant difference revealed. No adverse reaction was reported in EPO therapy group. Conclusion： EPO re- duces serum BNP and MMP-9, also alleviates the anemia in patients with CHF.

关 键 词：促红细胞生成素 心力衰竭 脑钠肽 基质金属蛋白酶 左心室质量指数 

分 类 号：R541.6[医药卫生—心血管疾病]